Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy.

Chronic Chagas cardiomyopathy (CCC) is one of the leading causes of morbidity and mortality due to cardiovascular disorders in endemic areas of Chagas disease (CD), a neglected tropical illness caused by the protozoan parasite Trypanosoma cruzi. CCC is characterized by parasite persistence and infla...

Full description

Saved in:

Bibliographic Details
Main Authors:	Priscila Silva Grijó Farani (Author), Beatriz Iandra da Silva Ferreira (Author), Khodeza Begum (Author), Glaucia Vilar-Pereira (Author), Isabela Resende Pereira (Author), Edith A Fernández-Figueroa (Author), Roberto Alejandro Cardenas-Ovando (Author), Igor C Almeida (Author), Sourav Roy (Author), Joseli Lannes-Vieira (Author), Otacilio Cruz Moreira (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2023-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pentoxifylline reverses chronic experimental Chagasic cardiomyopathy in association with repositioning of abnormal CD8+ T-cell response.
by: Isabela Resende Pereira, et al.
Published: (2015)

Tumor Necrosis Factor Is a Therapeutic Target for Immunological Unbalance and Cardiac Abnormalities in Chronic Experimental Chagas' Heart Disease
by: Isabela Resende Pereira, et al.
Published: (2014)

Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis.
by: Agustín Ciapponi, et al.
Published: (2020)

Access to benznidazole for Chagas disease in the United States-Cautious optimism?
by: Jonathan D Alpern, et al.
Published: (2017)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
by: Miriam Rolon, et al.
Published: (2022)

Ruthenium complex with benznidazole and nitric oxide as a new candidate for the treatment of chagas disease.
by: Renata Sesti-Costa, et al.
Published: (2014)

Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease.
by: Abilio Augusto Fragata-Filho, et al.
Published: (2016)

Benznidazole-Loaded Polymeric Nanoparticles for Oral Chemotherapeutic Treatment of Chagas Disease
by: Lucas Resende Dutra Sousa, et al.
Published: (2024)

Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study.
by: Clareci Silva Cardoso, et al.
Published: (2018)

Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments.
by: Lívia de Figueiredo Diniz, et al.
Published: (2013)

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.
by: Kota Yoshioka, et al.
Published: (2020)

Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment
by: Ana Lia Mazzeti, et al.
Published: (2023)

Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
by: Marcela S Rial, et al.
Published: (2017)

Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis.
by: Clara Crespillo-Andújar, et al.
Published: (2022)

Chronic Chagas cardiomyopathy
by: Vera Demarchi Aiello, et al.
Published: (2015)

The beneficial effect of fluoxetine on behavioral and cognitive changes in chronic experimental Chagas disease unveils the role of serotonin fueling astrocyte infection by Trypanosoma cruzi.
by: Glaucia Vilar-Pereira, et al.
Published: (2024)

Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole.
by: Claudia Magalhães Calvet, et al.
Published: (2020)

CD8low T cells expanded following acute Trypanosoma cruzi infection and benznidazole treatment are a relevant subset of IFN-γ producers.
by: Alessandro Marins-, et al.
Published: (2020)

Anti-Trypanosoma cruzi antibody profiling in patients with Chagas disease treated with benznidazole assessed by genome phage display.
by: Luis Antonio Rodriguez Carnero, et al.
Published: (2023)

Fat tissue regulates the pathogenesis and severity of cardiomyopathy in murine chagas disease.
by: Kezia Lizardo, et al.
Published: (2021)

Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.
by: Jaime Altcheh, et al.
Published: (2014)

Chagas Disease Cardiomyopathy: Immunopathology and Genetics
by: Edecio Cunha-Neto, et al.
Published: (2014)

Chagas cardiomyopathy in the context of the chronic disease transition.
by: Alicia I Hidron, et al.
Published: (2010)

MicroRNA Transcriptome Profiling in Heart of Trypanosoma cruzi-Infected Mice: Parasitological and Cardiological Outcomes.
by: Isabela Cunha Navarro, et al.
Published: (2015)

The centennial of the discovery of Chagas disease: facing the current challenges.
by: Joseli Lannes-Vieira, et al.
Published: (2010)

Diseño y preparación de formas farmacéuticas sólidas de benznidazol para el tratamiento de la enfermedad de Chagas
by: Sonia, Tarragona, et al.
Published: (2013)

TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas' heart disease.
by: Roberto Rodrigues Ferreira, et al.
Published: (2019)

Usefulness of real-time PCR during follow-up of patients treated with Benznidazole for chronic Chagas disease: Experience in two referral centers in Barcelona.
by: Elena Sulleiro, et al.
Published: (2020)

Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
by: Elena Pérez-Antón, et al.
Published: (2018)

A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment.
by: Elena Pérez-Antón, et al.
Published: (2021)

Unraveling the role of miRNAs as biomarkers in Chagas cardiomyopathy: Insights into molecular pathophysiology.
by: Heriks Gomes Ribeiro, et al.
Published: (2024)

Scientometrics analysis of research activity and collaboration patterns in Chagas cardiomyopathy.
by: Gregorio González-Alcaide, et al.
Published: (2018)

Heart function enhancement by an Nrf2-activating antioxidant in acute Y-strain Chagas disease, but not in chronic Colombian or Y-strain.
by: Hilton Antônio Mata-Santos, et al.
Published: (2024)

Myocardial protective effect and transcriptome profiling of Naoxintong on cardiomyopathy in zebrafish
by: Mengyan Hu, et al.
Published: (2021)

Pentoxifylline and its applications in dermatology
by: Iffat Hassan, et al.
Published: (2014)

GWAS loci associated with Chagas cardiomyopathy influences DNA methylation levels.
by: Desiré Casares-Marfil, et al.
Published: (2021)

GWAS loci associated with Chagas cardiomyopathy influences DNA methylation levels
by: Desiré Casares-Marfil, et al.
Published: (2021)

Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics.
by: Andrea Trochine, et al.
Published: (2014)

The use of pentoxifylline in male reproduction abnormalities
by: Aamir Jalal Al-Mosawi
Published: (2021)

Pentoxifylline in patients with oral submucous fibrosis
by: Ashwini Deshpande, et al.
Published: (2015)